Unnamed: 0,Unnamed: 1,Unnamed: 2,Unnamed: 3,Unnamed: 4,Biocon
,,,,,Result Update
,,,,,
,,,,,
Exhibit 7: Pegfilgrastim market share trend vs. peers,,,,,
Pegfilgrastim,,,,,
Player May'20 Jun'20 Sep'20,Dec'20,Mar'21,Apr'21,May'21,
brand name,,,,,
Fulphila Biocon/Mylan 14% 14% 15%,16%,16%,17%,17%,
Udenyca Coherus 49% 50% 51%,46%,43%,41%,39%,
Neulasta Amgen 35% 35% 31%,31%,26%,28%,25%,
Ziextenzo Sandoz 2% 2% 3%,7%,14%,14%,16%,
